Background: Chronic obstructive pulmonary disease (COPD) is associated with important chronic comorbid diseases, including diabetes, hypertension and cardiovascular diseases. As very limited data is available in India, the aim of the present study was to determine the relationship between COPD and the common, chronic comorbid conditions of diabetes mellitus (DM), hypertension (HTN), and cardiovascular diseases (CVD) and also to determine how these affect the clinical course of COPD.
Methods: All the COPD cohorts diagnosed as per Global Initiative for Chronic Obstructive Lung Disease-2013 (GOLD-2013) criteria were screened for DM, HTN, and CVD as per stipulated national and WHO guidelines.
Results: The prevalence of DM, HTN, and CVD in the 2432 COPD subjects was 25.94%, 37.25%, and 13.93%, respectively. In multivariate analyses, very severe COPD was associated with a higher risk of DM (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.2–2), HTN (OR 1.6, 95% CI 1.4–1.9), and CVD (OR 2.5, 95% CI 1.9–3.0).
Conclusion: A significant relationship was found between COPD and the presence of comorbid DM, HTN, and CVD. It was also found that subjects with advanced COPD were more likely to have at least two of these conditions and hugely affect the outcome of the disease. These findings suggest that the presence of COPD could provide a rationale to look for other comorbid disease and, conversely, that the presence of DM, HTN, or CVD might be the basis for the assessment of patients for airflow limitation and COPD as the tobacco smoking and advancing age were common risk factors.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
3. Mahishale V, Mahishale A, Patil B, Sindhuri A, Eti A. Screening for diabetes mellitus in patients with chronic obstructive pulmonary disease in tertiary care hospital in India. Niger Med J 2015;56:122–5.
4. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
5. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardio-vascular disease in COPD. Eur Respir J 2008; 32: 962–9.
6. Salvi S, Agarwal A. India needs a national COPD prevention and control program. J Assoc Physicians India 2012; 60: S5–7.
7. Mahishale V, Mahishale A, Patil B, Eti A, Lolly M, Khan S. Screening for chronic obstructive pulmonary disease in elderly subjects with dyspnoea and/or reduced exercise tolerance – A hospital based cross sectional study. Egypt J Chest Dis Tuberculosis 2015: 64: 567–71.
8. Directorate General of Health Services, India. National programme for prevention and control of cancer, diabetes, cardiovascular disease and stroke (NPCDCS). Available from: http://health.bih.nic.in/Docs/Guidelines-NPCDCS.pdf (Accessed on June 12, 2015).
9. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: The DOSE Index. Am J Respir Crit Care Med 2009;180:1189–95.
10. Rosenbaum L, Lamas D. Facing a “Slow-Motion Disaster” – The UN Meeting on Noncommunicable Diseases. New Engl J Med 2011; 365:2345–8.
11. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370:765–73.
12. Agusti A. Thorax 2014; 69:857–864.
13. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487–92.
14. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008;178:332–8.
15. Mahishale V. Ageing world: Health care challenges. J Sci Society 2015; 42: 138–43.
16. India Tuberculosis-Diabetes Study Group. Screening of patients with tuberculosis for diabetes mellitus in India. Trop Med Int Health 2013;18:636–45.
17. Jali MV, Mahishale VK, Hiremath MB. Bidirectional screening of tuberculosis patients for diabetes mellitus and diabetes patients for tuberculosis. Diabetes Metab J 2013;37:291–5.
18. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993;83:211–4.
19. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut- Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454–75.
20. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217–23.
21. Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood pressure related cardiovascular disease. J Hypertens 2000; 18(Suppl 1): S3–S6.
22. Mannino D, Swensenand Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962–9.
23. Mahishale V, Patil B, Lolly M, Eti A, Khan S. Prevalence of Smoking and Its Impact on Treatment Outcomes in Newly Diagnosed Pulmonary Tuberculosis Patients: A Hospital-Based Prospective Study. Chonnam Med J 2015;51:86–90.
25. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.